Idorsia has secured Breakthrough Therapy Designation from the U.S. Food and Drug Administration for daridorexant in children and adolescents aged 10 to under 18 with insomnia disorder, following positive Phase 2 findings demonstrating significant improvements in sleep duration. In the 165-patient randomized study, a single 50 mg dose increased objectively measured total sleep time by 50 minutes from baseline, compared with 20 minutes for placebo. Among participants with neurodevelopmental disorders, the improvement reached 64 minutes, highlighting the treatment’s potential in a pediatric population with limited approved pharmacological options.
The regulatory designation recognizes the preliminary clinical evidence and substantial unmet medical need in pediatric insomnia, where no medication is currently FDA-approved specifically for the condition. Idorsia plans to begin Phase 3 development during the second half of 2027, although daridorexant remains investigational for children and adolescents despite its existing approval for adult insomnia.
Why did the FDA grant breakthrough therapy designation to daridorexant for pediatric insomnia?
The FDA granted Breakthrough Therapy Designation based on results from Idorsia’s pediatric Phase 2 program, which demonstrated a statistically significant relationship between daridorexant dose and objectively measured sleep duration. The designation is intended for investigational treatments targeting serious conditions when preliminary clinical evidence suggests a potentially substantial improvement over available therapy.
For Idorsia, the decision enables closer interaction with the FDA and additional guidance during clinical development. These mechanisms can help address important questions about trial design, appropriate endpoints, safety monitoring and the evidence required for a potential regulatory application.
However, breakthrough designation does not constitute FDA approval or establish that daridorexant is sufficiently safe and effective for routine pediatric use. The company must still complete additional studies demonstrating a favorable benefit-risk profile before any authorization can be considered.
The designation is especially relevant because children with persistent insomnia may experience difficulties with attention, learning, emotional regulation and behavior. These effects can also increase the burden on families, particularly when children have coexisting developmental or behavioral conditions.
How much additional sleep did children achieve in Idorsia’s Phase 2 daridorexant study?
The multicenter Phase 2 study enrolled 165 children and adolescents aged 10 to under 18 with insomnia disorder. Participants were randomly assigned to receive daridorexant at 10 mg, 25 mg or 50 mg, or placebo, during a two-week treatment period.
The primary objective was to characterize the dose-response relationship using objectively measured total sleep time. Investigators employed polysomnography, a sleep-study technique that records physiological activity overnight, to assess changes following the first treatment dose.
The study met its primary endpoint, demonstrating a statistically significant dose-dependent improvement in total sleep time with a reported p-value of 0.0185. This result supports the conclusion that increasing daridorexant exposure was associated with greater sleep-duration improvements across the tested regimens.
At the 50 mg dose, total sleep time increased by approximately 50 minutes from baseline after the first administration, compared with approximately 20 minutes among placebo recipients. The numerical difference in improvement was therefore about 30 minutes in favor of the highest tested dose.
Caregiver assessments provided additional supportive evidence over the two-week treatment period. At the end of treatment, caregivers reported approximately 69 minutes of additional sleep with daridorexant 50 mg, compared with approximately 30 minutes in the placebo group.
The highest dose also produced the most consistent improvements across measures of sleep initiation, sleep maintenance and sleep quality. Nevertheless, the short study cannot establish whether these benefits remain durable during months or years of treatment.
Why were sleep improvements particularly encouraging in children with autism and ADHD?
More than half of the study participants had diagnosed or subthreshold neurodevelopmental conditions, including autism spectrum disorder or attention-deficit/hyperactivity disorder. These conditions can be associated with persistent sleep difficulties that complicate daytime functioning and family routines.
Among participants with neurodevelopmental disorders, daridorexant 50 mg increased objectively measured sleep time by approximately 64 minutes from baseline. The corresponding increase with placebo was approximately 27 minutes, producing a numerical difference of around 37 minutes.
The findings are clinically interesting because poor sleep may worsen difficulties with concentration, emotional regulation and behavioral functioning in children with developmental conditions. Increasing sleep duration could potentially reduce some of these burdens, although the Phase 2 study did not establish improvements in the underlying neurodevelopmental disorders.
Idorsia reported that treatment effects were observed among participants both with and without neurodevelopmental conditions. However, subgroup findings require confirmation in larger trials designed to evaluate the consistency and clinical relevance of treatment responses.
Professor Carmen Schröder of Strasbourg University Hospitals, who presented the Phase 2 findings, indicated that the dose-response relationship and improvements across several sleep measures support further investigation. She also emphasized the importance of the neurodevelopmental subgroup because insomnia can add substantially to the challenges experienced by affected children and their families.
How does daridorexant’s dual orexin receptor mechanism differ from conventional sleep medicines?
Daridorexant is a dual orexin receptor antagonist designed to reduce excessive wake-promoting signaling in the brain. Orexin is a neurotransmitter system involved in maintaining wakefulness, making it an important target for medicines intended to improve sleep initiation and maintenance.
By blocking both orexin receptors, daridorexant aims to reduce the biological signals that keep patients awake rather than broadly suppressing central nervous system activity. This mechanism differs from several traditional sedative-hypnotic approaches.
Idorsia developed the medicine with pharmacokinetic properties intended to maintain activity during the night while limiting residual exposure the following morning. In adults, daridorexant has an approximate terminal half-life of eight hours and does not produce active metabolites or significant accumulation with repeated dosing.
These characteristics could be relevant for pediatric treatment because excessive morning sleepiness may interfere with school performance, attention and routine activities. However, the effect of prolonged treatment on daytime functioning in children requires further investigation.
Daridorexant is already marketed as QUVIVIQ for adults with insomnia disorder, providing an established foundation of adult clinical and commercial experience. Its existing approval does not extend to pediatric patients, and adult efficacy or safety findings cannot substitute for age-appropriate clinical evidence.
What did the pediatric Phase 2 trial reveal about safety and next-morning sleepiness?
Idorsia reported that daridorexant was generally well tolerated across the tested pediatric doses, including 50 mg, the highest recommended adult dose. The company stated that the observed safety profile at this dose was similar to placebo during the two-week study.
No adverse events suggesting drug abuse were observed during treatment, and investigators reported no indications of withdrawal symptoms following discontinuation. Assessments also suggested numerical improvements in morning alertness rather than increased next-day sleepiness.
These findings offer preliminary reassurance because medications affecting sleep and wakefulness require particular attention to cognitive functioning, daytime alertness and behavioral effects in younger patients. Nevertheless, the small population and brief exposure period limit conclusions about uncommon adverse events or risks associated with prolonged administration.
Longer studies will need to assess sustained tolerability, withdrawal effects, daytime functioning and possible consequences of repeated treatment. Safety evaluation will also be important among children receiving other medications for coexisting neurodevelopmental conditions.
The favorable early findings therefore support further testing without establishing that daridorexant is safer than other sleep interventions or appropriate for all children experiencing insomnia.
What comes next for Idorsia’s Phase 3 program and potential pediatric insomnia approval?
Idorsia is preparing a Phase 3 development program intended to confirm the efficacy and safety of daridorexant in pediatric insomnia disorder. The company expects to initiate the program during the second half of 2027 while incorporating feedback from regulatory authorities.
The breakthrough designation should provide opportunities for more frequent FDA interactions as investigators finalize the study protocol and determine how to evaluate clinically meaningful improvements. Additional attention will likely focus on treatment duration, age-related considerations and the relationship between nighttime sleep benefits and daytime functioning.
The complete Phase 2 dataset is also undergoing consideration for publication in a scientific journal. Detailed peer-reviewed findings could provide further information about dose selection, variability in treatment responses and safety outcomes across patient subgroups.
The company’s existing adult insomnia franchise offers relevant experience with daridorexant, but pediatric approval will depend on evidence generated specifically in children and adolescents. Even if future trials confirm improved sleep duration, regulators must determine whether the overall benefits justify the risks in the intended population.
For families affected by persistent pediatric insomnia, the breakthrough designation represents meaningful progress toward evaluating a possible new treatment option. However, daridorexant remains investigational for pediatric use, and longer controlled studies are essential before its role in clinical practice can be established.
